Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Periostin is up-regulated in high grade and high stage prostate cancer

Authors: Verena Tischler, Florian R Fritzsche, Peter J Wild, Carsten Stephan, Hans-Helge Seifert, Marc-Oliver Riener, Thomas Hermanns, Ashkan Mortezavi, Josefine Gerhardt, Peter Schraml, Klaus Jung, Holger Moch, Alex Soltermann, Glen Kristiansen

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far.

Methods

Here, we evaluated periostin expression in prostate cancer cells and peritumoural stroma immunohistochemically in two independent prostate cancer cohorts, including a training cohort (n = 93) and a test cohort (n = 325). Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign prostatic tissues (n = 38) were also analyzed.

Results

In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and in 11 of 38 benign prostate glands (28.9%). Increased periostin expression in carcinoma cells was significantly associated with high Gleason score (p < 0.01) and advanced tumour stage (p < 0.05) in the test cohort. Whereas periostin expression was weak or absent in the stroma around normal prostate glands, strong periostin expression in tumour stroma was found in most primary and metastatic prostate cancers. High stromal periostin expression was associated with higher Gleason scores (p < 0.001). There was a relationship between stromal periostin expression and shortened PSA relapse free survival times in the training cohort (p < 0.05).

Conclusions

Our data indicate that periostin up-regulation is related to increased tumour aggressiveness in prostate cancer and might be a promising target for therapeutical interventions in primary and metastatic prostate cancer.
Appendix
Available only for authorised users
Literature
1.
Takeshita S, Kikuno R, Tezuka K, Amann E: Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993, 294 (Pt 1): 271-278.CrossRefPubMedPubMedCentral
2.
Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A: Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999, 14 (7): 1239-1249. 10.1359/jbmr.1999.14.7.1239.CrossRefPubMed
3.
Oshima A, Tanabe H, Yan T, Lowe GN, Glackin CA, Kudo A: A novel mechanism for the regulation of osteoblast differentiation: transcription of periostin, a member of the fasciclin I family, is regulated by the bHLH transcription factor, twist. Journal of cellular biochemistry. 2002, 86 (4): 792-804. 10.1002/jcb.10272.CrossRefPubMed
4.
Kruzynska-Frejtag A, Machnicki M, Rogers R, Markwald RR, Conway SJ: Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation. Mechanisms of development. 2001, 103 (1-2): 183-188. 10.1016/S0925-4773(01)00356-2.CrossRefPubMed
5.
Kruzynska-Frejtag A, Wang J, Maeda M, Rogers R, Krug E, Hoffman S, Markwald RR, Conway SJ: Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction. Dev Dyn. 2004, 229 (4): 857-868. 10.1002/dvdy.10453.CrossRefPubMed
6.
Wilde J, Yokozeki M, Terai K, Kudo A, Moriyama K: The divergent expression of periostin mRNA in the periodontal ligament during experimental tooth movement. Cell and tissue research. 2003, 312 (3): 345-351. 10.1007/s00441-002-0664-2.CrossRefPubMed
7.
Nakazawa T, Nakajima A, Seki N, Okawa A, Kato M, Moriya H, Amizuka N, Einhorn TA, Yamazaki M: Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J Orthop Res. 2004, 22 (3): 520-525. 10.1016/j.orthres.2003.10.007.CrossRefPubMed
8.
Li P, Oparil S, Feng W, Chen YF: Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J Appl Physiol. 2004, 97 (4): 1550-1558. 10.1152/japplphysiol.01311.2003. discussion 1549CrossRefPubMed
9.
Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF: Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Molecular and cellular biology. 2004, 24 (9): 3992-4003. 10.1128/MCB.24.9.3992-4003.2004.CrossRefPubMedPubMedCentral
10.
Lindner V, Wang Q, Conley BA, Friesel RE, Vary CP: Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler Thromb Vasc Biol. 2005, 25 (1): 77-83.PubMed
11.
Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, et al: Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med. 2008, 205 (2): 295-303. 10.1084/jem.20071297.CrossRefPubMedPubMedCentral
12.
Litvin J, Zhu S, Norris R, Markwald R: Periostin family of proteins: therapeutic targets for heart disease. Anat Rec A Discov Mol Cell Evol Biol. 2005, 287 (2): 1205-1212.CrossRefPubMed
13.
Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004, 5 (4): 329-339. 10.1016/S1535-6108(04)00081-9.CrossRefPubMed
14.
Yan W, Shao R: Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem. 2006, 281 (28): 19700-19708. 10.1074/jbc.M601856200.CrossRefPubMed
15.
Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002, 62 (18): 5358-5364.PubMed
16.
Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T, Lemoine NR: Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene. 2007, 26 (14): 2082-2094. 10.1038/sj.onc.1210009.CrossRefPubMed
17.
Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Buchler MW, Giese NA, Friess H: Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology. 2007, 132 (4): 1447-1464. 10.1053/j.gastro.2007.01.031.CrossRefPubMed
18.
Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE: Gene expression in poorly differentiated papillary thyroid arcinomas. Thyroid. 2006, 16 (2): 161-175. 10.1089/thy.2006.16.161.CrossRefPubMed
19.
Forsti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, Grzybowska E, Pamula J, Pekala W, Hallmans G, et al: Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast cancer research and treatment. 2007, 101 (1): 83-93. 10.1007/s10549-006-9265-1.CrossRefPubMed
20.
Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M: Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol. 2008, 21 (8): 1044-53. 10.1038/modpathol.2008.77.CrossRefPubMed
21.
Gonzalez HE, Gujrati M, Frederick M, Henderson Y, Arumugam J, Spring PW, Mitsudo K, Kim HW, Clayman GL: Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Archives of otolaryngology--head & neck surgery. 2003, 129 (7): 754-759. 10.1001/archotol.129.7.754.CrossRef
22.
Kanno A, Satoh K, Masamune A, Hirota M, Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, et al: Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. International journal of cancer. 2008, 122 (12): 2707-2718. 10.1002/ijc.23332.CrossRefPubMed
23.
Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Kii I, Horie H, Nagai H, Kudo A, et al: Periostin Is Expressed in Pericryptal Fibroblasts and Cancer-associated Fibroblasts in the Colon. J Histochem Cytochem. 2008, 56 (8): 753-764. 10.1369/jhc.2008.951061.CrossRefPubMedPubMedCentral
24.
Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyauchi M, Takata T: Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer research. 2006, 66 (14): 6928-6935. 10.1158/0008-5472.CAN-05-4540.CrossRefPubMed
25.
Li JS, Sun GW, Wei XY, Tang WH: Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol. 2007, 13 (39): 5261-5266.CrossRefPubMedPubMedCentral
26.
Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, et al: Expression of periostin in human breast cancer. Journal of clinical pathology. 2008, 61 (4): 494-498. 10.1136/jcp.2007.052506.CrossRefPubMed
27.
Puppin C, Fabbro D, Dima M, Di Loreto C, Puxeddu E, Filetti S, Russo D, Damante G: High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. The Journal of endocrinology. 2008, 197 (2): 401-408. 10.1677/JOE-07-0618.CrossRefPubMed
28.
Sasaki H, Dai M, Auclair D, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y, Chen LB: Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas. Cancer. 2001, 92 (4): 843-848. 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P.CrossRefPubMed
29.
Sasaki H, Lo KM, Chen LB, Auclair D, Nakashima Y, Moriyama S, Fukai I, Tam C, Loda M, Fujii Y: Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res. 2001, 92 (8): 869-873.CrossRefPubMed
30.
Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, Yamakawa Y, Fuji Y: Expression of the periostin mRNA level in neuroblastoma. Journal of pediatric surgery. 2002, 37 (9): 1293-1297. 10.1053/jpsu.2002.34985.CrossRefPubMed
31.
Siriwardena BS, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Hatano H, Tilakaratne WM, Miyauchi M, Takata T: Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. British journal of cancer. 2006, 95 (10): 1396-1403. 10.1038/sj.bjc.6603431.CrossRefPubMedPubMedCentral
32.
Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res. 2008, 14 (22): 7430-7437. 10.1158/1078-0432.CCR-08-0935.CrossRefPubMed
33.
Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G: Expression of the Extracellular Matrix Protein Periostin in Liver Tumors and Bile Duct Carcinomas. Histopathology. 2010
34.
Soltermann A, Ossola R, Kilgus-Hawelski S, von Eckardstein A, Suter T, Aebersold R, Moch H: N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer. 2008, 114 (2): 124-133. 10.1002/cncr.23349.CrossRefPubMed
35.
Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK, Shirasawa S: The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate. 2009, 69 (13): 1398-403. 10.1002/pros.20988.CrossRefPubMed
36.
Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008, 98 (3): 604-610. 10.1038/sj.bjc.6604199.CrossRefPubMedPubMedCentral
37.
Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, Kim HR, Cher ML, Sarkar FH: Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells. 2008, 26 (6): 1425-1435. 10.1634/stemcells.2007-1076.CrossRefPubMedPubMedCentral
38.
Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW: Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol. 2007, 213 (2): 374-383. 10.1002/jcp.21223.CrossRefPubMed
39.
Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T, Li MC, Lin YH: Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol. 2007, 14 (11): 1034-1039. 10.1111/j.1442-2042.2007.01866.x.CrossRefPubMed
40.
Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM: Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008, 68 (7): 2479-2488. 10.1158/0008-5472.CAN-07-2559.CrossRefPubMed
41.
Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, Neri D: A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics. 2006, 5 (11): 2083-2091. 10.1074/mcp.M600164-MCP200.CrossRefPubMed
42.
Sasaki H, Dai M, Auclair D, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y, Chen LB: Serum level of the periostin, a homologue of an insect cell adhesion molecule, in thymoma patients. Cancer letters. 2001, 172 (1): 37-42. 10.1016/S0304-3835(01)00633-4.CrossRefPubMed
43.
Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, et al: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 2008, 54 (5): 1097-1106. 10.1016/j.eururo.2007.11.034.CrossRefPubMed
44.
Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T: Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol. 2007, 22 (10): 1167-1174.PubMed
Metadata
Title
Periostin is up-regulated in high grade and high stage prostate cancer
Authors
Verena Tischler
Florian R Fritzsche
Peter J Wild
Carsten Stephan
Hans-Helge Seifert
Marc-Oliver Riener
Thomas Hermanns
Ashkan Mortezavi
Josefine Gerhardt
Peter Schraml
Klaus Jung
Holger Moch
Alex Soltermann
Glen Kristiansen
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-273

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Low salivary testosterone levels in patients with breast cancer

Research article

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

Research article

Tocotrienols are good adjuvants for developing cancer vaccines

Research article

Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions

Research article

Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells

Research article

Differential detection of alternatively spliced variants of Ciz1 in normal and cancer cells using a custom exon-junction microarray
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits